Home » Topics » BioWorld Science

BioWorld Science
RSS

P&U reports most potent K(ATP)-channel blocker yet discovered

May 10, 1996

Mavik aproved for marketing in U.S.

May 10, 1996

RS-66252 selective for AT1 receptors in vitro

May 10, 1996

Antihypertensive activity reported for FR-149581

May 10, 1996

E. Merck continues to investigate angiotensin II blockers

May 10, 1996

R-844: Novel steroid for asthma

May 10, 1996

Daicel reports neuronal cell protectant

May 10, 1996

Galanthamine effective in delaying AD progression

May 10, 1996

GR-175737: H3 antagonist for cognition disorders

May 10, 1996

Bayer reports K+ channel modulators for CNS disorders

May 10, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.